scholarly journals Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS‐CoV‐2 infection

2020 ◽  
Vol 190 (5) ◽  
Author(s):  
Katharine Orf ◽  
Srdan Rogosic ◽  
Daniel Dexter ◽  
Phil Ancliff ◽  
Saket Badle ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Induction Chemotherapy ◽  
Lymphoblastic Leukaemia ◽  
Newly Diagnosed

scholarly journals Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes

2021 ◽  
Vol 11 (11) ◽  
Author(s):  
James B. Studd ◽  
Alex J. Cornish ◽  
Phuc H. Hoang ◽  
Philip Law ◽  
Ben Kinnersley ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Darwinian Evolution ◽  
Driver Mutations ◽  
Expression Data ◽  
Newly Diagnosed ◽  
Comprehensive Picture ◽  
Cancer Drivers ◽  
Sequencing And Expression ◽  
Mutational Processes

AbstractTo obtain a comprehensive picture of composite genetic driver events and clonal dynamics in subtypes of paediatric acute lymphoblastic leukaemia (ALL) we analysed tumour-normal whole genome sequencing and expression data from 361 newly diagnosed patients. We report the identification of both structural drivers, as well as recurrent non-coding variation in promoters. Additionally we found the transcriptional profile of histone gene cluster 1 and CTCF altered tumours shared hallmarks of hyperdiploid ALL suggesting a ‘hyperdiploid like’ subtype. ALL subtypes are driven by distinct mutational processes with AID mutagenesis being confined to ETV6-RUNX1 tumours. Subclonality is a ubiquitous feature of ALL, consistent with Darwinian evolution driving selection and expansion of tumours. Driver mutations in B-cell developmental genes (IKZF1, PAX5, ZEB2) tend to be clonal and RAS/RTK mutations subclonal. In addition to identifying new avenues for therapeutic exploitation, this analysis highlights that targeted therapies should take into account composite mutational profile and clonality.

Outcome of adult acute lymphoblastic leukaemia following induction chemotherapy with modified MRC UKALL XII/ECOG E2993 protocol

2012 ◽  
Vol 38 (2) ◽  
pp. 43-46 ◽  
Author(s):  
N Islam ◽  
MM Rahman ◽  
MA Aziz ◽  
F Begum ◽  
ABM Yunus
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Induction Chemotherapy ◽  
Induction Therapy ◽  
Lymphoblastic Leukaemia ◽  
Phase 1 ◽  
Response Rates ◽  
Complete Response ◽  
Developed Countries ◽  
Phase 2 ◽  
Cure Rates

Cure rates for adult acute lymphoblastic leukaemia (ALL) in developing countries are significantly lower because of problems unique to these countries. Recent studies have reported complete response rates for any induction regimen of more than 90% in adult ALL patients. This study was conducted to evaluate the response rate of induction chemotherapy in adult ALL patients in the Department of Haematology, Bangabandhu Sheikh Mujib Medical University, from January 2007 to December 2008.  In this observational study, 35 newly diagnosed ALL patients classified either as L1/L2 according to  French-American-British (FAB) classification, aged between 15 to 60 years were assigned for  induction therapy with modified MRC UKALL XII/ECOG E2993 protocol. But ultimately 30 patients completed therapy and available for statistical analysis. Among the studied 30 cases 12(40%) patients after phase 1 and overall 24(80%) patients after phase 2 induction therapy, achieved morphologic complete remission (CR). After phase 2 therapy 6(20%) patients fell in the group of non responders (NR) as the blast percentage was ?5% at the time of bone marrow evaluation. This study shows the response rates in adult ALL with induction therapy slightly below the anticipated response rates of developed countries which may be due to little modification of the original protocol. DOI: http://dx.doi.org/10.3329/bmrcb.v38i2.12879 Bangladesh Med Res Counc Bull 2012; 38: 43-46

Sign in / Sign up

Export Citation Format

Share Document